Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp T.IGX

Alternate Symbol(s):  IGXT

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Receives Positive DSMB Recommendation for Montelukast VersaFilm® Phase 2a Trial

GlobeNewswire October 9, 2019

IntelGenx Announces Resubmission of RIZAPORT® New Drug Application

GlobeNewswire September 26, 2019

IntelGenx to Present at the H.C. Wainwright 21st Annual Global Investment Conference

GlobeNewswire September 3, 2019

IntelGenx Reports Second Quarter 2019 Financial Results

GlobeNewswire August 8, 2019

IntelGenx to Report Second Quarter 2019 Financial Results on August 8, 2019 - Conference Call to Follow

GlobeNewswire August 1, 2019

IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer's Disease

GlobeNewswire July 10, 2019

IntelGenx Announces Addition of Peterborough's Kawartha Centre as Montelukast VersaFilm® Phase 2a Clinical Trial Site

GlobeNewswire June 19, 2019

IntelGenx Announces Addition of Ottawa Montelukast VersaFilm® Phase 2a Clinical Trial Site; First Patient in Study Completes 26-Week Treatment

GlobeNewswire June 10, 2019

IntelGenx Receives First Shipment of Cannabis Extract from Tilray® for Production of Cannabis-Infused Oral Film

GlobeNewswire May 28, 2019

IntelGenx to Join the Quebec Pavilion at BIO 2019 International Convention

GlobeNewswire May 23, 2019

IntelGenx Reports First Quarter 2019 Financial Results

GlobeNewswire May 9, 2019

IntelGenx Announces the Appointment of André Godin as President and Chief Financial Officer

GlobeNewswire May 8, 2019

IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

GlobeNewswire May 8, 2019

IntelGenx to Report First Quarter 2019 Financial Results on May 9, 2019 - Conference Call to Follow

GlobeNewswire May 2, 2019

IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology

GlobeNewswire May 1, 2019

IntelGenx to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 25, 2019

IntelGenx to Promote Oral Films CDMO Services at CPhI North America

GlobeNewswire April 23, 2019

IntelGenx to Promote VetaFilm™ Oral Film Technology at Human Biotech & Animal Health Business Partnering Summit

GlobeNewswire April 8, 2019

IntelGenx Presents at 14th International Conference on Alzheimer’s and Parkinson’s Disease

GlobeNewswire April 4, 2019

IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA

GlobeNewswire April 2, 2019